ADARx Pharmaceuticals
PublicADARx Pharmaceuticals is now publicly traded
The data on this page reflects ADARx Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Strategic
May 14, 2025
Total Funding Raised
$666.5M
Company Overview
ADARx Pharmaceuticals is a biotechnology company that develops innovative therapeutics using a proprietary RNA targeting platform and advanced delivery technologies to treat genetic, cardiovascular, and central nervous system diseases.
Sector
Biotech
Verticals
HealthTech, Life Sciences
AI Layer
Non-AI
Keywords
ADARx Pharmaceuticals Comparables
Compare ADARx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanegene Bio | 83% | |
| Arrowhead Pharmaceuticals | 81% | |
| Silence Therapeutics plc | 78% |
ADARx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | May 14, 2025 | ||||
| Series C | Aug 9, 2023 | ||||
| Series B Extension | Jan 20, 2023 | ||||
| Series B | Sep 8, 2021 | ||||
| Series A | Nov 1, 2020 |
Key People
Founding team and executive leadership
ADARx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C |
| Sirona Capital | Series B, Series B Extension |
| Bain Capital Life Sciences | Series C |
| TCG Crossover | Series C |
| Cormorant Asset Management | Series C |
| OrbiMed | Series B Extension, Series C, Series A, Series B |
| Commodore Capital | Series C |
Recent news
Latest coverage and updates
- receives_financingSep 26, 2026
ADARx Pharmaceuticals, Inc. receives $535M through an IPO and private placement in Sep '26 to support clinical development of its siRNA therapies beyond the liver.
- has_valuationSep 26, 2026
ADARx Pharmaceuticals, Inc. had valuation of $2B on Sep 25th '26.
- receives_financingSep 25, 2026
ADARx Pharmaceuticals, Inc. received financing of $446M in IPO on Sep 25th '26.
- hiresSep 21, 2026
ADARx Pharmaceuticals, Inc. hired Chris Storgard as Chief Medical Officer on Apr 2nd '24.
- goes_publicSep 21, 2026
ADARx Pharmaceuticals, Inc. went public on Sep 21st '26.
ADARx Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access